Previous 10 | Next 10 |
2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
2024-04-15 08:40:27 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Financial information for Viracta Therapeutics Read the full article on Seeking Alpha For...
2024-04-15 08:21:07 ET More on Pre-market losers & stocks. OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable populati...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that topline results from Stage 1 of the NAVAL-1...
2024-03-08 08:51:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viracta Therapeutics (NASDAQ: VIRX ) just reported results for the fourth quarter of 2023. Viracta Therapeutics reported earnings per share of -35 cents. This was below th...
2024-03-07 17:29:15 ET More on Viracta Therapeutics Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earnings data for Viracta Therapeutics Read the full article on Seeking Alpha For further details see: Viracta Therapeutics GAAP EPS...
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024 Completed enrollme...
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of 2024 SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasda...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc. Website:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...